HC Wainwright & Co. Maintains Buy on Calidi Biotherapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Calidi Biotherapeutics (AMEX:CLDI) but lowered the price target from $11 to $2.
March 21, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Calidi Biotherapeutics' price target was significantly reduced from $11 to $2 by HC Wainwright & Co., although the Buy rating was maintained.
The substantial reduction in the price target for Calidi Biotherapeutics by a reputable analyst firm, while maintaining a Buy rating, suggests a reassessment of the company's near-term prospects. This could lead to negative investor sentiment in the short term, as the new price target significantly lowers expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100